(REPL) Replimune - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 782m USD | Total Return: -11.9% in 12m
Avg Turnover: 28.4M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Interest Coverage Ratio -48.6 is critical
Altman Z'' -9.81 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Replimune Group Inc (REPL) is a clinical-stage biotechnology firm specializing in the development of oncolytic immunotherapies. The company utilizes a proprietary platform based on the Herpes Simplex Virus-1 (HSV-1) to engineer therapies that selectively replicate within tumors while stimulating a systemic immune response against cancer cells.
The companys pipeline is led by RP1, currently being evaluated for various solid tumors. Additional candidates include RP2, which incorporates anti-CTLA-4 proteins, and RP3, designed to express immune-activating ligands. Unlike traditional chemotherapy, oncolytic viruses function as a dual-action mechanism by directly lysing tumor cells and acting as an in situ vaccine to prime T cells.
The biotechnology sector often requires significant capital expenditure and lengthy regulatory cycles, with success heavily dependent on Phase 2 and Phase 3 clinical trial outcomes. For a deeper look into the companys valuation metrics and historical performance, ValueRay provides comprehensive data tools. Headquartered in Massachusetts, Replimune operates within the high-growth immunotherapy segment of the oncology market.
- RP1 clinical trial data and BLA filing for melanoma
- FDA regulatory approval timeline for lead oncolytic immunotherapy candidate
- Cash runway and capital allocation for commercial launch preparations
- Competitive landscape in skin cancer immunotherapy and combination treatments
| Net Income: -314.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.85 > 0.02 and ΔFCF/TA -53.11 > 1.0 |
| NWC/Revenue: 15.6k% < 20% (prev 12.4k%; Δ 3.28k% < -1%) |
| CFO/TA -0.83 > 3% & CFO -277.9m > Net Income -314.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (92.2m) vs 12m ago 10.41% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.31% > 50% (prev 0.67%; Δ -0.36% > 0%) |
| Interest Coverage Ratio: -48.62 > 6 (EBIT TTM -315.0m / Interest Expense TTM 6.48m) |
| A: 0.69 (Total Current Assets 280.4m - Total Current Liabilities 50.1m) / Total Assets 333.6m |
| B: -3.57 (Retained Earnings -1.19b / Total Assets 333.6m) |
| C: -0.67 (EBIT TTM -315.0m / Avg Total Assets 468.6m) |
| D: 1.71 (Book Value of Equity 210.5m / Total Liabilities 123.1m) |
| Altman-Z'' = -9.81 = D |
| DSRI: 2.65 (Receivables 2.96m/3.07m, Revenue 1.47m/4.04m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.81 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 0.36 (Revenue 1.47m / 4.04m) |
| TATA: -0.11 (NI -314.9m - CFO -277.9m) / TA 333.6m) |
| Beneish M = -1.66 (Cap -4..+1) = CCC |
As of June 12, 2026, the stock is trading at USD 8.62 with a total of 2,031,004 shares traded.
Over the past week, the price has changed by -12.66%,
over one month by +130.48%,
over three months by +9.11% and
over the past year by -11.86%.
Replimune has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy REPL.
- StrongBuy: 3
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.7 | -45.8% |
P/B = 3.8631
Revenue TTM = 1.47m USD
EBIT TTM = -315.0m USD
EBITDA TTM = -311.4m USD
Long Term Debt = 47.6m USD (from longTermDebt, last quarter)
Short Term Debt = 4.08m USD (from shortTermDebt, last quarter)
Debt = 105.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 28.7m
Net Debt = -164.1m USD (calculated: Debt 105.1m - CCE 269.1m)
Enterprise Value = 617.9m USD (782.0m + Debt 105.1m - CCE 269.1m)
Interest Coverage Ratio = -48.62 (Ebit TTM -315.0m / Interest Expense TTM 6.48m)
EV/FCF = -2.18x (Enterprise Value 617.9m / FCF TTM -283.3m)
FCF Yield = -45.84% (FCF TTM -283.3m / Enterprise Value 617.9m)
FCF Margin = -19.2k% (FCF TTM -283.3m / Revenue TTM 1.47m)
Net Margin = -21.4k% (Net Income TTM -314.9m / Revenue TTM 1.47m)
Gross Margin = unknown ((Revenue TTM 1.47m - Cost of Revenue TTM 5.80m) / Revenue TTM)
Tobins Q-Ratio = 1.85 (Enterprise Value 617.9m / Total Assets 333.6m)
Interest Expense / Debt = 6.17% (Interest Expense 6.48m / Debt 105.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -248.8m (EBIT -315.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.60 (Total Current Assets 280.4m / Total Current Liabilities 50.1m)
Debt / Equity = 0.50 (Debt 105.1m / totalStockholderEquity, last quarter 210.5m)
Debt / EBITDA = 0.53 (negative EBITDA) (Net Debt -164.1m / EBITDA -311.4m)
Debt / FCF = 0.58 (negative FCF - burning cash) (Net Debt -164.1m / FCF TTM -283.3m)
Total Stockholder Equity = 306.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.19% (Net Income -314.9m / Total Assets 333.6m)
RoE = -102.7% (Net Income TTM -314.9m / Total Stockholder Equity 306.6m)
RoCE = -88.92% (EBIT -315.0m / Capital Employed (Equity 306.6m + L.T.Debt 47.6m))
RoIC = -86.55% (negative operating profit) (NOPAT -248.8m / Invested Capital 287.5m)
WACC = 8.45% (E(782.0m)/V(887.0m) * Re(8.93%) + D(105.1m)/V(887.0m) * Rd(6.17%) * (1-Tc(0.21)))
Discount Rate = 8.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 15.56%
[DCF] Fair Price = unknown (Cash Flow -283.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 3.22 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.60 | Chg30d=+0.96% | Revisions=-20% | Analysts=3
[Analyst] Revisions Ratio: -20%